Monday January 19, 2026

Happy Monday, and a fine Dr. Martin Luther King Jr. Day.

If there’s a throughline this week, it’s scale—AI platforms pushing into healthcare, strategics expanding portfolios, and smaller teams advancing toward pivotal trials.

8 things to watch this week:

1. 🧠 Anthropic expands into healthcare a week after OpenAI launched a similar product

Anthropic has launched Claude for Healthcare, a HIPAA-ready platform that embeds its AI models into clinical, payer, consumer health, and life sciences workflows to rival OpenAI’s healthcare push.

Business Insider

2. 🤝 ATEC and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion

Alphatec (ATEC) and Theradaptive have formed a strategic partnership giving ATEC exclusive U.S. rights to commercialize Theradaptive’s OsteoAdapt osteoinductive bone graft for spinal fusion, which is built on the AMP2 platform and carries multiple FDA Breakthrough Device Designations. The deal combines upfront, milestone, and royalty payments and will support Theradaptive’s pivotal OASIS spinal fusion trial and manufacturing scale-up in a U.S. spine market exceeding $10 billion annually.

PR Newswire

3. 🤝 Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation

Boston Scientific has agreed to acquire Valencia Technologies and its FDA-approved, coin-sized eCoin tibial nerve stimulation implant, expanding the company’s urology portfolio for treating urge urinary incontinence in people with overactive bladder, with the deal expected to close in the first half of 2026 and have an immaterial impact on 2026 adjusted EPS.

Boston Scientific

4. 🧪 Before You Launch, Pressure-Test the Story

Strong clinical data doesn’t automatically translate to commercial traction. RŌG Health helps medical device teams identify where messaging, market fit, and execution plans break down using their proprietary Commercial Readiness Diagnostic (CRD).

Contact RŌG for more info →

5. 🛡️ FDA Clears At-Home Neuromodulation Device for Major Depressive Disorder

The FDA has cleared ProlivRx, a wearable at-home neuromodulation headset that delivers external occipital and trigeminal nerve stimulation as an adjunct treatment for adults with major depressive disorder who have not responded adequately to at least one antidepressant.

EMPR

6. 🛡️ Medtronic Diabetes announces FDA clearance for MiniMed Go™ Smart MDI system featuring Instinct sensor made by Abbott

Medtronic has received FDA 510(k) clearance for its MiniMed Go smart MDI system, which connects the InPen smart insulin pen with Abbott’s Instinct CGM sensor via the MiniMed Go app to provide real-time dosing guidance and glucose insights for insulin-requiring people with type 1 and type 2 diabetes.

PR Newswire

7. 🤝 StimLabs® and Geistlich Expand Their Partnership with a New Product Anticipated Q2 2026

StimLabs and Geistlich are expanding their regenerative medicine partnership to co-develop and launch a new novel wound care product expected in Q2 2026, building on their existing Derma-Gide® distribution agreement and combined scientific and commercial strengths.

PR Newswire

8. 📈 Nanochon closes $4.1M Seed Prime II Funding Round

Nanochon has closed an oversubscribed $4.1 million Seed Prime II round led by cultivate(MD), bringing its total funding to $11.3 million to advance its Chondrograft knee cartilage implant through first-in-human trials and toward a future pivotal study.

PR Newswire

---

🧭 About The Pathway

The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.

Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items. Interested in becoming a sponsor? Contact us.